Wedbush analyst David Nierengarten lowered the firm’s price target on Xencor (XNCR) to $26 from $31 and keeps an Outperform rating on the shares following quarterly results. The firm notes the nearest data catalyst for shares is initial data for XmAb819 in ccRCC, expected at a medical meeting in Q4 2025. XmAb541 continues in dose escalation for CLDN6+ tumors, with identification of target dose levels anticipated later this year. The Phase 2 XENITH-UC study evaluating TL1A mAb XmAb942 is now underway, enrolling moderate to severe ulcerative colitis patients who progressed on at least one prior conventional or advanced therapy, Wedbush adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XNCR:
- Xencor’s XmAb942 Shows Promising Efficacy and Strategic Advancements, Earning a Buy Rating
- Xencor’s Strategic Advances and Promising Pipeline Drive Buy Rating
- Xencor, Inc. Reports Revenue Growth Amidst Continued Losses
- Xencor reports Q2 EPS (41c) , consensus (71c)
- Xencor’s XmAb541 Study Completion: A Potential Game-Changer in Oncology